University System of Maryland

Guilford Pharmaceuticals, Inc.

Otsuka Pharmaceutical Company, Limited

Eisai Inc.

Mcdaniel College

Rena S Lapidus

Dana Victor Ferraris

Gregory S Hamilton

Barbara S Slusher

Takashi Tsukamoto

Bridget Duvall

Paul F Jackson

Keith M Maclin

Eric Yanjun Wang

Edward A Sausville

Ashkan Emadi

Brandon Carter-Cooper

Pavel Majer

Steven Fletcher

Herman O Sintim

Jie Zhou

Mariola Sadowska

Changhao Wang

The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.

Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia

Provided are compositions comprising linked diaryl compounds that possess anticancer properties. Methods of use are also disclosed herein. The method comprises administering an effective amount of a compound described herein to an individual in need thereof.

Linked diaryl compounds with anticancer properties and methods of using the same

The present invention provides certain tetrahydrouridine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of making and using such compounds.

Certain compounds, compositions and methods

The present invention provides a formulation comprising dichloroacetate and arsenic trioxide. The present invention also provides a method of treating cancer by administering a therapeutically effective amount of dichloroacetate and arsenic trioxide.

Compositions and methods for the treatment of cancers

The present invention relates to N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) inhibitors enzyme activity, pharmaceutical compositions comprising such inhibitors, and methods of their use to inhibit NAALADase enzyme activity, thereby effecting neuronal activities, inhibiting angiogenesis, and treating glutamate abnormalities, compulsive disorders, prostate diseases, pain and diabetic neuropathy.

NAALADase inhibitors useful as pharmaceutical compounds and compositions

The present disclosure relates to a method of inhibiting angiogenesis comprising administering a N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) inhibitor to a patient in need thereof, and a pharmaceutical composition comprising an anti-angiogenic effective amount of a NAALADase inhibitor and a pharmaceutically acceptable carrier.

Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors

The present invention relate to thio-substituted pentanedioic acid derivatives that inhibit N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) enzyme activity, pharmaceutical compositions comprising the same, and methods of using the same to inhibit NAALADase enzyme activity, to effect neuronal activities, to inhibit angiogenesis, and to treat glutamate abnormalities, compulsive disorders and prostate diseases.

Thio-substituted pentanedioic acid derivatives

The present invention relates to novel methods and kits for quantitating N-Acetylated .alpha.-Linked Acidic Dipeptidase (NAALADase) enzyme activity in biological samples, including prostate biopsies, seminal fluid, ejaculate, prostatic fluid, blood, saliva, and urine, for the purpose of identifying and differentiating between prostate carcinoma, benign prostatic hyperplasia, and normal prostate.

Growing community of inventors

Baltimore, MD, United States of America

Rena S Lapidus